Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

McGraw

Lublin

. Interferon beta and glatiramer acetate therapy. Neurotherapeutics 2013; 10: 2–18.

Olea

Díaz-Mancebo

Picazo

. Thrombotic microangiopathy associated with use of interferon-beta. Int J Nephrol Renovasc Dis 2012; 5: 97–100.

Wallbach

Gröne

Kitze

. Nephrotic syndrome in a multiple sclerosis patient receiving long-term interferon beta therapy. Am J Kidney Dis 2013; 61: 786–789.

Ledinek

Jazbec

SŠ

Drinovec

. Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: A case report. Mult Scler 2009; 15: 885–886.

Petousi

Thomas

. Interferon-β-induced pulmonary sarcoidosis in a 30-year-old woman treated for multiple sclerosis: A case report. J Med Case Rep 2012; 6: 344.

Chakravarty

Harris

Schreiner

. Sarcoidosis triggered by interferon-beta treatment of multiple sclerosis: A case report and focused literature review. Semin Arthritis Rheum 2012; 42: 206–212.

Orvain

Augusto

Besson

. Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis. Int Urol Nephrol 2013; Feb 24 [Epub ahead of print].

Morita

Yoshimura

. Glomerulonephritis in sarcoidosis. Clin Exp Nephrol 2006; 10: 85–86.

Reder

Feng

. Aberrant type I interferon regulation in autoimmunity: Opposite directions in MS and SLE shaped by evolution and body ecology. Front Immunol 2013; 4: 1–13

10.

Axtell

Raman

Steinman

. Type I Interferons: Beneficial in Th1 and detrimental in Th17 autoimmunity. Clin Rev Allerg Immunol 2013; 44: 114–120.

Interferon beta-related nephropathy and interstitial lung disease: a new association and a long-term warning

Abstract

Get full access to this article

References